Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Unknown × Everolimus × Clear all

Phase

Phase 2 23 Phase 1/2 5 Phase 1 5 Phase NA 3 Phase 3 3 Phase 4 1 Phase 2/3 1

Status

Recruiting 3 Withdrawn 1 Unknown 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 1 Intellectual Disability 1 Autistic Disorder 1

Interventions

Docetaxel 16 Cisplatin 16 Capecitabine 15 Drug Therapy 14 Cyclophosphamide 13 Oxaliplatin 12 Fluorouracil 12 Radiotherapy 11 Paclitaxel 9 apatinib 8 Epirubicin 7 Doxorubicin 7 Decitabine 7 sintilimab 6 Methotrexate 6 Gemcitabine 6 Carboplatin 6 Busulfan 6 anlotinib 5 XELOX 5 Pemetrexed 5 Leucovorin 5 Etoposide 5 Dexamethasone 5 lenvatinib 4 camrelizumab 4 Surgical Procedures, Operative 4 Radiosurgery 4 Neoadjuvant Therapy 4 Cytarabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01730209 2015-05-05

RAPIT

Erasmus Medical Center

Phase 2/3 Unknown

Autistic Disorder, Intellectual Disability, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡